| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2014: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Outline of Final Research Achievements |
Searching for bone marrow involvement in patients with multiple myeloma (MM), whole-body imaging of FDG-PET/CT(FDG), 11C-methionine PET/CT(Met), and 11C-4-thiothymidine PET/CT(4DST) were compared. Among the 57 patients, the number of patients diagnosed as stage 3 (more than 21 lesions) was 6 with FDG, 10 with Met and 11 with 4DST. Addition of Met or 4DST to FDG induced up-staging of about 20% of patients. Up-staged patients had bone pain more frequently than the other. Based on the standard criteria for the diagnosis of active myeloma using the percentage of marrow plasma cells, significant differences were found between the FDG and Met findings and between the FDG and 4DST findings, but no significant difference was observed between the Met and 4DST findings. Based on cytological diagnostic criteria, Met and 4DST were more sensitive than FDG for the detection of active lesions of MM.
|
